Clinilabs and Ambulatory Monitoring. Inc., Form Strategic Alliance
Clinilabs has entered into a strategic alliance withAmbulatory Monitoring, Inc. (AMI), a medical device and service company.
AMI, located in Ardsley, NY, provides equipment for monitoring physiological functioning in ambulatory subjects. The company’s series of Motionlogger® Actigraphs are commercial devices for 24-hour monitoring of activity and sleep and have been validated through use in hundreds of studies in numerous clinical populations. AMI’s activity monitors can be applied in clinical trials of therapeutics for sleep, psychiatric, pain, hyperactivity, dermatologic (e.g., itch), and cardiovascular disorders, among others. AMI also providesthe original PVT-192 Psychomotor Vigilance Task Monitor.
The alliance brings together AMI’s instrumentation with Clinilabs’ core laboratory. Clinilabs’ core laboratory aggregates and processes electrocardiographic (ECG), polysomnographic (PSG), electroencephalographic (EEG), and electromyographic (EMG) data for clinical studies, offering pharmaceutical companies centralized services that standardize data obtained in multicenter trials. Centralized actigraphy has been offered jointly by Clinilabs and AMI since 2005.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
